Skip to main content
. 2021 Sep 14;2021:3825155. doi: 10.1155/2021/3825155

Table 1.

Characteristics of DR nondevelopment group and DR development group.

Characteristics Non-DR development (n = 300) DR development (n = 30) P value
Age (years) 58.33 ± 10.64 61.30 ± 9.31 †0.142
Sex (female) 155 (51.7%) 12 (40.0%) ‡0.223
Diabetes duration (years) 6.00, 9.00 9.50, 8.00 §0.009∗∗
BMI (kg/m2) 25.62 ± 3.63 25.72 ± 3.55 †0.889
HBP 123 (41.0%) 13 (43.3%) ‡0.804
SBP (mmHg) 127.81 ± 17.28 130.03 ± 18.97 †0.505
DBP (mmHg) 76.03 ± 11.96 75.9 ± 11.08 †0.953
HbA1c (%) 7.23 ± 1.55 8.38 ± 2.26 †0.010
Albuminuria (+~+++) 11 (3.7%) 5 (16.7%) ‡0.002∗∗
Scr (mg/dL) 84.89 ± 23.84 103.49 ± 43.64 †0.028
eGFR (mL/min/1.73 m2) 79.11 ± 21.27 71.82 ± 29.60 †0.197
TP (g/L) 70.74 ± 6.08 70.3 ± 8.88 †0.794
ALB (g/L) 44.29 ± 4.17 42.8 ± 5.47 †0.071
HGB (g/dL) 134.12 ± 15.51 137.57 ± 19.7 †0.259
HCT (%) 39.05 ± 4.23 39.58 ± 5.75 †0.523
FPG (mg/dL) 6.89, 2.55 7.81, 5.82 §0.023
TC (mg/dL) 4.27 ± 0.89 4.05 ± 1.01 †0.204
LDL (mg/dL) 2.50 ± 0.75 2.34 ± 0.74 †0.260
TRIG (mg/dL) 1.31, 1.00 1.89, 1.32 §0.011
Oral hypoglycemic 265 (88.3%) 28 (93.3%) ‡0.408
Insulin (unit) 15.00, 27.00 16.50, 20.00 §0.743
Antihypertension 94 (31.3%) 10 (33.3%) ‡0.822
Lipid-lowering 224 (74.7%) 21 (70.0%) ‡0.577

Results are expressed as mean ± SD, percentages, or as medians, IQR; P values were compared by independent t-test, Mann-Whitney U test or χ2 test as appropriate. P < 0.05, ∗∗P < 0.01.†Values for comparisons between groups by independent samples t-test. ‡Values for comparisons between groups by χ2 test. §Values for comparisons between groups by Mann-Whitney U test. DR: diabetic retinopathy; BMI: body mass index; HBP: hypertension; SBP: systolic blood pressure; DBP: diastolic blood pressure; HbA1c: hemoglobin A1c; Scr: serum creatinine; eGFR: estimated glomerular filtration rate; TP: total protein; ALB: serum albumin; HGB: hemoglobin; HCT: hematocrit; FPG: fasting plasma glucose; TC: total cholesterol; LDL: low-density lipoprotein; TRIG: triglyceride.